HCG supplement did not accelerate tunica albuginea remodeling to facilitate penile growth.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 10 2023
02 10 2023
Historique:
received:
01
12
2022
accepted:
17
07
2023
medline:
4
10
2023
pubmed:
3
10
2023
entrez:
2
10
2023
Statut:
epublish
Résumé
Penile size is closely concerned and short penis contributes serious sexual dysfunction and tremendous psychological problems to couples. Androgen is essential for penile development and testosterone replacement is recommended to patients with micropenis. We previously proved that inhibiting activity of lysyl oxidase (Anti-lysyl oxidase, Anti-LOX) combined with vacuum erectile device (VED) lengthened penis by remodeling tunica albuginea. We thus explored whether HCG supplement could accelerate tunica albuginea remodeling (induced by Anti-LOX + VED) to promote penile growth. Forty-two SD male rats (4 weeks old) were purchased and divided into 7 groups: control, Anti-LOX, HCG, VED (with a negative aspirated pressure of - 300 mmHg), Anti-LOX + VED, HCG + VED, and Anti-LOX + HCG + VED. After an intervention for 4 weeks, all rats' penile length, exposed penile length, and erectile function were measured. Serum samples were collected to detect hormone levels and penile corpus cavernosum were harvested for histo-pathological analysis. All intervention groups showed significantly longer penis than controlled rats. Anti-LOX sharply increased penile length and exposed length by 15% and 9% respectively, this lengthening effect was more obvious in Anti-LOX + VED group (26% and 19%, respectively). Although HCG promoted penile length by 8%, this effect was slight for exposed length (3%). Moreover, Anti-LOX + HCG + VED dramatically increased penile length and exposed length by 22% and 18%, respectively, which was similar with that in Anti-LOX + VED (26% and 19%, respectively). HCG dramatically stimulated testosterone and dihydrotestosterone secretions than control group, whether with or without Anti-LOX and VED; while it induced more AR expression than other groups. Finally, all procedures did not improve or deteriorate normal erectile function. Although we verified that Anti-LOX + VED lengthened penis by inducing tunica albuginea remodeling, however, HCG supplement did not synergize with Anti-LOX + VED to accelerate albuginea remodeling to facilitate penile growth.
Identifiants
pubmed: 37783699
doi: 10.1038/s41598-023-38888-y
pii: 10.1038/s41598-023-38888-y
pmc: PMC10545796
doi:
Substances chimiques
Testosterone
3XMK78S47O
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16519Informations de copyright
© 2023. Springer Nature Limited.
Références
J Urol. 1998 Sep;160(3 Pt 2):1054-7; discussion 1079
pubmed: 9719275
J Urol. 1993 Aug;150(2 Pt 2):657-60
pubmed: 8326617
Br J Urol. 1997 Jan;79(1):47-53
pubmed: 9043496
Circulation. 2002 Nov 5;106(19):2503-9
pubmed: 12417550
J Sex Med. 2013 Jan;10(1):294-303
pubmed: 22512935
Int Urol Nephrol. 2003;35(2):237-45
pubmed: 15072502
J Clin Endocrinol Metab. 2002 Jul;87(7):3125-35
pubmed: 12107212
Urology. 2007 Sep;70(3):572-5
pubmed: 17905119
Sci Rep. 2017 Nov 2;7(1):14949
pubmed: 29097758
Indian J Urol. 2013 Oct;29(4):288-91
pubmed: 24235789
Am J Physiol. 1990 Jan;258(1 Pt 1):E46-50
pubmed: 2301571
Differentiation. 2020 Jan - Feb;111:98-114
pubmed: 31783219
Eur Urol. 2006 Apr;49(4):609-11
pubmed: 16439051
BJU Int. 2018 Nov;122(5):889-897
pubmed: 29772111
J Pediatr Endocrinol Metab. 2016 Feb;29(2):173-7
pubmed: 26352087
Int J Immunopathol Pharmacol. 2015 Sep;28(3):421-5
pubmed: 25816396
Transl Androl Urol. 2020 Mar;9(Suppl 2):S160-S170
pubmed: 32257856
J Urol. 2001 Oct;166(4):1451-4
pubmed: 11547110
Endocr Connect. 2018 Sep 1;:
pubmed: 30352406
Am J Physiol Heart Circ Physiol. 2005 Nov;289(5):H2228-33
pubmed: 15951346
Johns Hopkins Med J. 1980 May;146(5):177-84
pubmed: 7382242
Toxicol Appl Pharmacol. 2010 Apr 15;244(2):156-61
pubmed: 20045017
Adv Exp Med Biol. 2002;511:41-54; discussion 54-6
pubmed: 12575755
J Sex Marital Ther. 2010;36(2):118-23
pubmed: 20169492
Nat Rev Urol. 2012 Sep;9(9):499-507
pubmed: 22890302
Johns Hopkins Med J. 1980 Apr;146(4):156-63
pubmed: 7366061
Am J Physiol Heart Circ Physiol. 2012 Oct 15;303(8):H1067-75
pubmed: 22904155
Atherosclerosis. 1998 Sep;140(1):135-45
pubmed: 9733224
J Urol. 1995 Aug;154(2 Pt 2):825-9
pubmed: 7609189
Pediatr Endocrinol Rev. 2014 Sep;12(1):42-5
pubmed: 25345084
J Urol. 1996 Aug;156(2 Pt 2):783-7; discussion 787
pubmed: 8683783
J Steroid Biochem Mol Biol. 1996 Mar;57(5-6):301-13
pubmed: 8639466
Arch Pediatr Adolesc Med. 2010 Dec;164(12):1152-7
pubmed: 21135345
Int J Androl. 2010 Feb;33(1):e144-52
pubmed: 19656234
BJU Int. 1999 Dec;84(9):1093-4
pubmed: 10571642
Eur J Endocrinol. 2006 Jan;154(1):125-9
pubmed: 16382001
Asian J Androl. 2020 Sep-Oct;22(5):485-492
pubmed: 31736474
Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H1-9
pubmed: 20472764
Johns Hopkins Med J. 1980 Nov;147(5):175-81
pubmed: 7441936
Mol Cell Endocrinol. 1993 Jan;90(2):219-29
pubmed: 8495802
J Urol. 1997 Sep;158(3 Pt 2):1113-8
pubmed: 9258152
Andrology. 2020 Nov;8(6):1884-1894
pubmed: 32578359
J Investig Med. 1997 Oct;45(8):441-7
pubmed: 9394096
Br J Urol. 1994 May;73(5):566-71
pubmed: 8012781
Curr Opin Urol. 2008 Nov;18(6):583-8
pubmed: 18832943
Lancet. 1979 Nov 10;2(8150):983-6
pubmed: 91775
Andrologia. 2022 Dec;54(11):e14617
pubmed: 36257721
Asian J Androl. 2014 Nov-Dec;16(6):817-23
pubmed: 24994782
J Pediatr. 1999 May;134(5):579-83
pubmed: 10228293
Asian J Androl. 2016 May-Jun;18(3):446-51
pubmed: 26289397
BJU Int. 2011 Apr;107(8):1278-82
pubmed: 20868389
J Urol. 1994 Aug;152(2 Pt 2):734-9
pubmed: 8022007
Andrologia. 2018 Sep;50(7):e13051
pubmed: 29806152
J Steroid Biochem Mol Biol. 1993 May;45(5):333-43
pubmed: 8499343
Toxicol Appl Pharmacol. 2009 Sep 15;239(3):258-67
pubmed: 19524603
Eur Urol. 2010 Nov;58(5):773-80
pubmed: 20674151